Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 604

1.

Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat.

Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B.

BMC Bioinformatics. 2015 Feb 25;16(1):63. doi: 10.1186/s12859-015-0478-3.

2.

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, Usmani SZ, Bailey C, Petty N, Van Rhee F, Barlogie B.

Clin Case Rep. 2015 Mar;3(3):183-92. doi: 10.1002/ccr3.180. Epub 2015 Feb 13.

3.

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B.

Leukemia. 2015 Mar 10. doi: 10.1038/leu.2015.65. [Epub ahead of print]

PMID:
25753926
4.

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.

Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD Jr, Barlogie B.

Leukemia. 2012 Feb 2. doi: 10.1038/leu.2015.15. [Epub ahead of print]

PMID:
25640885
5.

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E.

J Clin Oncol. 2015 Feb 20;33(6):657-64. doi: 10.1200/JCO.2014.57.9961. Epub 2015 Jan 20.

PMID:
25605835
6.

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.

Atrash S, Tullos A, Panozzo S, Bhutani M, Van Rhee F, Barlogie B, Usmani SZ.

Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93. No abstract available.

7.

Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.

Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F.

J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059.

8.

Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.

Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.

9.

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.

Usmani SZ, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, Steward D, Panozzo S, Petty N, Hoering A, Waheed S, Van Rhee F, Crowley J, Barlogie B.

Leukemia. 2014 Dec;28(12):2413-5. doi: 10.1038/leu.2014.248. Epub 2014 Aug 25. No abstract available.

PMID:
25151956
10.

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.

Bam R, Venkateshaiah SU, Khan S, Ling W, Randal SS, Li X, Zhang Q, van Rhee F, Barlogie B, Epstein J, Yaccoby S.

Blood Cancer J. 2014 Aug 1;4:e234. doi: 10.1038/bcj.2014.54.

11.

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma.

Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, Zhang Q, Edmondson R, Hoering A, Crowley J, Barlogie B.

Leukemia. 2014 Dec;28(12):2410-3. doi: 10.1038/leu.2014.232. Epub 2014 Jul 31. No abstract available.

12.

CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S.

Blood. 2014 Sep 25;124(13):2051-60. doi: 10.1182/blood-2014-02-555813. Epub 2014 Jul 24.

PMID:
25061178
13.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP.

Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15. Review.

14.

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis.

Papanikolaou X, Johnson S, Garg T, Tian E, Tytarenko R, Zhang Q, Stein C, Barlogie B, Epstein J, Heuck C.

Oncotarget. 2014 Jun 30;5(12):4118-28.

15.

Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance.

Yang JD, Girotra M, Restrepo A, Waheed S, Barlogie B, Duarte-Rojo A.

Ann Hepatol. 2014 Jul-Aug;13(4):461-5.

PMID:
24927619
16.

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

Srkalovic G, Hussein MA, Hoering A, Zonder JA, Popplewell LL, Trivedi H, Mazzoni S, Sexton R, Orlowski RZ, Barlogie B.

Cancer Med. 2014 Oct;3(5):1275-83. doi: 10.1002/cam4.276. Epub 2014 Jun 10.

17.

The future of autologous stem cell transplantation in myeloma.

van Rhee F, Giralt S, Barlogie B.

Blood. 2014 Jul 17;124(3):328-33. doi: 10.1182/blood-2014-03-561985. Epub 2014 Jun 3. Review.

PMID:
24894774
18.

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.

19.

Muscular Relapse in a Patient With Multiple Myeloma.

Waheed S, Zhu H, Waheed MA, Kumar M, Barlogie B.

J Clin Oncol. 2014 Apr 28. [Epub ahead of print] No abstract available.

PMID:
24778395
20.

Strange bedfellows: mitotically active chronic myeloid leukemia in molecular complete remission, detected in focal lesion of myeloma.

Guru Murthy GS, Sawyer J, Alapat D, Samant R, Barlogie B.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):e127-9. doi: 10.1016/j.clml.2014.02.008. Epub 2014 Feb 28. No abstract available.

PMID:
24685577
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk